Andreas Argyrides
Stock Analyst at Oppenheimer
(4.43)
# 256
Out of 4,840 analysts
105
Total ratings
50%
Success rate
22.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LQDA Liquidia | Downgrades: Underperform | $13 | $15.35 | -15.31% | 7 | May 19, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Outperform | $14 → $4 | $0.62 | +548.51% | 5 | May 16, 2025 | |
| KRRO Korro Bio | Maintains: Outperform | $155 → $90 | $13.80 | +552.17% | 1 | May 13, 2025 | |
| PRQR ProQR Therapeutics | Maintains: Outperform | $15 → $9 | $1.67 | +438.92% | 1 | May 13, 2025 | |
| IFRX InflaRx | Initiates: Outperform | $6 | $1.85 | +224.32% | 1 | May 8, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | $47 → $15 | $14.57 | +2.95% | 8 | Jan 17, 2025 | |
| ASND Ascendis Pharma | Reiterates: Outperform | $181 | $162.00 | +11.73% | 9 | Nov 15, 2024 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $35 | $13.36 | +161.98% | 1 | Oct 16, 2024 | |
| LRMR Larimar Therapeutics | Initiates: Outperform | $26 | $1.87 | +1,290.37% | 1 | Oct 16, 2024 | |
| RGLS Regulus Therapeutics | Reiterates: Outperform | $7 | $7.89 | -11.28% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $104 | $38.93 | +167.15% | 14 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.86 | +479.37% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $1.20 | +650.00% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $14.98 | +26.84% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $9 | $2.35 | +282.98% | 4 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $19.25 | +50.65% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $9.71 | +116.27% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $37.90 | +491.03% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $25.82 | +120.76% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.78 | - | 6 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.92 | +662.86% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $4.12 | +142.72% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.47 | +2,012.82% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $57.55 | +21.63% | 6 | Aug 1, 2023 |
Liquidia
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $15.35
Upside: -15.31%
Rani Therapeutics Holdings
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $0.62
Upside: +548.51%
Korro Bio
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $13.80
Upside: +552.17%
ProQR Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $1.67
Upside: +438.92%
InflaRx
May 8, 2025
Initiates: Outperform
Price Target: $6
Current: $1.85
Upside: +224.32%
Keros Therapeutics
Jan 17, 2025
Downgrades: Neutral
Price Target: $47 → $15
Current: $14.57
Upside: +2.95%
Ascendis Pharma
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $162.00
Upside: +11.73%
Benitec Biopharma
Oct 16, 2024
Initiates: Outperform
Price Target: $35
Current: $13.36
Upside: +161.98%
Larimar Therapeutics
Oct 16, 2024
Initiates: Outperform
Price Target: $26
Current: $1.87
Upside: +1,290.37%
Regulus Therapeutics
Aug 14, 2024
Reiterates: Outperform
Price Target: $7
Current: $7.89
Upside: -11.28%
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $38.93
Upside: +167.15%
Jun 25, 2024
Initiates: Outperform
Price Target: $5
Current: $0.86
Upside: +479.37%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $1.20
Upside: +650.00%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $14.98
Upside: +26.84%
Mar 7, 2024
Maintains: Outperform
Price Target: $4 → $9
Current: $2.35
Upside: +282.98%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $19.25
Upside: +50.65%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $9.71
Upside: +116.27%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $37.90
Upside: +491.03%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $25.82
Upside: +120.76%
Nov 16, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.78
Upside: -
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.92
Upside: +662.86%
Oct 10, 2023
Initiates: Outperform
Price Target: $10
Current: $4.12
Upside: +142.72%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.47
Upside: +2,012.82%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $57.55
Upside: +21.63%